Sequent Scientific Faces Evaluation Shift Amidst Strong Profit Growth and Debt Concerns
Sequent Scientific, a small-cap pharmaceutical company, has recently experienced a change in its evaluation, reflecting a shift in market sentiment. Despite a strong annual return and significant quarterly net profit growth, the company faces challenges such as declining operating profits and a high Debt to EBITDA ratio, indicating financial complexities.
Sequent Scientific, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the technical landscape, moving from a mildly bullish stance to a more neutral position. The company's current stock price stands at 183.70, down from a previous close of 187.05. Over the past year, Sequent Scientific has demonstrated a notable return of 50.57%, significantly outpacing the Sensex's 6.07% return. However, the company has faced challenges, including a -4.45% CAGR growth in operating profits over the last five years and a high Debt to EBITDA ratio of 9.34 times, indicating potential difficulties in servicing its debt.
Despite these challenges, Sequent Scientific reported a remarkable 717.32% growth in net profit for the quarter ending March 2025, alongside consistent positive results over the last five quarters. The company’s return on equity averages 4.85%, reflecting low profitability per unit of shareholders' funds.
The adjustment in evaluation underscores the complexities of Sequent Scientific's financial health and market position.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
